Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion description "[We have developed a cancer-specific immunotherapy called modified CTL therapy, which involves adoptive immunotherapy of autologous cancer-specific bulk CTLs after active immunization of autologous or allogeneic cancer cells screened as in vitro stimulators according to their ability to induce autologous cancer-specific CTLs (ACS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion evidence source_evidence_literature NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion SIO_000772 11078795 NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion wasDerivedFrom befree-20150227 NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion wasGeneratedBy ECO_0000203 NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- befree-20150227 importedOn "2015-02-27" NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.